TITLE

Medical oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS59
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Clinical use of nested RT-PCR for PSA during the treatment of prostate cancer by androgen withdrawal therapy,' by E. Beraldi et al.
ACCESSION #
9708236641

 

Related Articles

  • Prostate cancer: 9. Treatment of advanced disease. Gleave, Martin E.; Bruchovsky, Nick; Moore, Malcolm J.; Venner, Peter // CMAJ: Canadian Medical Association Journal;1/26/99, Vol. 160 Issue 2, p225 

    Discusses the treatment of advanced prostate cancer. The case of a 70-year-old man; Details about androgens and the prostate gland; Androgen withdrawal therapy; Responses to androgen withdrawal therapy; Controversial issues in advanced prostate cancer; Quality-of-life issues; Hormone-refractory...

  • A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer. Oliver, Timothy; Wilson, Peter; Ansell, Wendy; Philp, Tim; Chinegwundoh, Frank; Shamash, Jonathan; Shaw, Greg; Ahmad, Amar // Urologia Internationalis;Feb2018, Vol. 100 Issue 2, p172 

    Objective: A locally advanced Gleason 4 + 4 prostate cancer patient who was on self-medication with intermittent anti-androgen monotherapy (iAAm) over 14 years suggested that raised testosterone was not dangerous and this suggestion needed investigating....

  • Diethylstilboestrol (1 mg) in the Management of Castration-Resistant Prostate Cancer. Turo, Rafal; Tan, Kenny; Thygesen, Helene; Sundaram, Subramanian K.; Chahal, Rohit; Prescott, Stephen; Cross, William R. // Urologia Internationalis;Apr2015, Vol. 94 Issue 3, p307 

    Objective: To investigate the efficacy of diethylstilboestrol (DES) in patients with advanced prostate cancer refractory to androgen suppression. Methods: This retrospective study comprises 194 patients with prostate cancer treated with DES (1 mg daily) between 1976 and 2010. Study outcome...

  • Androgen Deprivation Therapy for Prostate Cancer Does Not Increase Cardiovascular Mortality in the Long Term. Wilcox, Chantelle; Kautto, Allison; Steigler, Allison; Denham, James W. // Oncology;Feb2012, Vol. 82 Issue 1, p56 

    Objective: To determine if 6 months of neo-adjuvant androgen deprivation is associated with the long-term risk of cardiac mortality. Methods: In the TROG 96.01 trial, 802 men with locally advanced prostate cancer were randomized to radiotherapy either alone or with 3 or 6 months of neo-adjuvant...

  • Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis. Bosco, Cecilia; Crawley, Danielle; Adolfsson, Jan; Rudman, Sarah; Van Hemelrijck, Mieke // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer. To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all...

  • Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Yang, David D.; Mahal, Brandon A.; Muralidhar, Vinayak; Boldbaatar, Ninjin; Labe, Shelby A.; Nezolosky, Michelle D.; Vastola, Marie E.; Beard, Clair J.; Martin, Neil E.; Mouw, Kent W.; Orio, Peter F.; King, Martin T.; Nguyen, Paul L.; Orio, Peter F 3rd // Cancer (0008543X);Dec2017, Vol. 123 Issue 24, p4832 

    Background: Conservative management of aggressive prostate cancer in the elderly without definitive therapy has been associated with a 10-year prostate cancer-specific mortality of approximately 50%. The authors examined the prevalence of definitive therapy in elderly patients with...

  • Early prostate cancer best left alone--Treatment riskier than cancer.  // HealthFacts;Jul93, Vol. 18 Issue 170, p1 

    Reports on the modalities of treating prostatic cancer. Prostate Patient Outcomes Research Team; Radical prostatectomy; Prostate-specific antigen blood test; Radiation therapy; Watchful waiting; Nerve-sparing technique.

  • Patients say they want aggressive treatment for prostate cancer.  // Modern Medicine;Jul96, Vol. 64 Issue 7, p31 

    Reports that a Harris Poll survey of 1,000 newly diagnosed patients has found that men who have prostate cancer want the most aggressive therapy available. Other survey results.

  • Prostate-cancer vaccine.  // Men's Health;Jul/Aug97, Vol. 12 Issue 6, p126 

    Presents information about prostate-cancer vaccine. Effectivity of the vaccine; Effect of a cancerous prostate cells left after surgery; Testing the vaccine in patients whose cancer has returned after surgery.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics